Ra Pharmaceuticals (RARX) Reports Positive Top-line Data from Phase 2 Trial of Zilucoplan in Patients with Generalized Myasthenia Gravis
Tweet Send to a Friend
Ra Pharmaceuticals, Inc. (NASDAQ: RARX) today announced positive top-line results from the Company’s Phase 2 clinical trial evaluating zilucoplan for ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
